Despite all the changes, it seems likely that compounding pharmacies will continue to offer GLP-1 drugs, at least for the foreseeable future, says Brunner: Some patients will be able to maintain these therapies at a price point they can afford in a customized formulation. The Takeaway The FDA ordered compounding pharmacies to stop producing and selling copies of GLP-1 injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, as official shortages have ended
Cycle Length: Minimum 24 weeks
Switch the delivery method first, stabilize, then consider switching the compound
When researchers observed that patients taking these drugs also experienced significant weight loss, pharmaceutical companies began developing higher-dose formulations specifically for weight management
Our licensed providers understand these concerns, which is why InjectCo offers a supportive, physician-guided program tailored for patients across West Virginia
According to a recent analysis by IQVIA, first-time prescriptions for GLP-1 therapies have surged from a mere 3% of diabetes patients in 2021 to nearly 25% by early 2025
